Thema: US5011471027
KRYS, US5011471027
wall-street-621097_1920.jpg - Foto: THN
Krystal Biotech stock: KB113 data show broad tumor regression
Krystal Biotech stock is in focus after Zacks highlighted early KB113 findings in Gorlin syndrome. The company has begun FDA talks on advanced development.
ad-hoc-news.de, heute 03:02 Uhr
KRYS, US5011471027
HC Wainwright keeps USD 361 target for Krystal Biotech stock ...
HC Wainwright kept its USD 361.00 target on October 15, 2026. Krystal Biotech stock costs EUR 289.80 on October 20, 2026.
ad-hoc-news.de, 20.10.26 19:53 Uhr
KRYS, US5011471027
Krystal Biotech stock falls 4.1 percent 17.2 percent below ...
The target rose to USD 416.00 from USD 386.00 on October 15, 2026. Krystal Biotech stock was USD 316.58 on October 16, 2026, down 4.1 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 19:23 Uhr
KRYS, US5011471027
HC Wainwright keeps USD 361.00 target for Krystal Biotech ...
Results are due November 2, 2026. Krystal Biotech stock costs EUR 295.80 on October 15, 2026, up 0.34 percent on Nasdaq versus its October 14 prior close.
ad-hoc-news.de, 15.10.26 20:32 Uhr
KRYS, US5011471027
Goldman starts coverage of Krystal Biotech stock at USD ...
Second-quarter revenue was USD 119.22 million. Krystal Biotech stock costs EUR 296.35 on October 8, 2026, plus 2.22 percent after EUR 289.90.
ad-hoc-news.de, 08.10.26 20:26 Uhr
KRYS, US5011471027
Goldman Sachs sets USD 441 target for Krystal Biotech stock ...
Second-quarter revenue was USD 119.22 million, and diluted EPS was USD 1.79. Krystal Biotech stock had a EUR 290.25 prior close on October 5, 2026.
ad-hoc-news.de, 07.10.26 00:23 Uhr
KRYS, US5011471027
Krystal Biotech stock gained 3.90 percent on October 5
Krystal Biotech stock closed at USD 334.85 on October 5 after revenue reached USD 119.2 million in Q2. Analysts see a USD 365.40 average target.
ad-hoc-news.de, 06.10.26 09:52 Uhr
KRYS, US5011471027
Krystal Biotech stock weighs Q2 growth against USD 441 target ...
